210 related articles for article (PubMed ID: 28402963)
1. Identification of serum inflammatory markers as classifiers of lung cancer mortality for stage I adenocarcinoma.
Meaney CL; Zingone A; Brown D; Yu Y; Cao L; Ryan BM
Oncotarget; 2017 Jun; 8(25):40946-40957. PubMed ID: 28402963
[TBL] [Abstract][Full Text] [Related]
2. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier.
Seike M; Yanaihara N; Bowman ED; Zanetti KA; Budhu A; Kumamoto K; Mechanic LE; Matsumoto S; Yokota J; Shibata T; Sugimura H; Gemma A; Kudoh S; Wang XW; Harris CC
J Natl Cancer Inst; 2007 Aug; 99(16):1257-69. PubMed ID: 17686824
[TBL] [Abstract][Full Text] [Related]
3. An Aggressive Subtype of Stage I Lung Adenocarcinoma with Molecular and Prognostic Characteristics Typical of Advanced Lung Cancers.
Dama E; Melocchi V; Dezi F; Pirroni S; Carletti RM; Brambilla D; Bertalot G; Casiraghi M; Maisonneuve P; Barberis M; Viale G; Vecchi M; Spaggiari L; Bianchi F; Di Fiore PP
Clin Cancer Res; 2017 Jan; 23(1):62-72. PubMed ID: 27358486
[TBL] [Abstract][Full Text] [Related]
4. HOXA9 methylation and blood vessel invasion in FFPE tissues for prognostic stratification of stage I lung adenocarcinoma patients.
Lissa D; Ishigame T; Noro R; Tucker MJ; Bliskovsky V; Shema S; Beck JA; Bowman ED; Harris CC; Robles AI
Lung Cancer; 2018 Aug; 122():151-159. PubMed ID: 30032824
[TBL] [Abstract][Full Text] [Related]
5. A novel protein-based prognostic signature improves risk stratification to guide clinical management in early-stage lung adenocarcinoma patients.
Martínez-Terroba E; Behrens C; de Miguel FJ; Agorreta J; Monsó E; Millares L; Sainz C; Mesa-Guzman M; Pérez-Gracia JL; Lozano MD; Zulueta JJ; Pio R; Wistuba II; Montuenga LM; Pajares MJ
J Pathol; 2018 Aug; 245(4):421-432. PubMed ID: 29756233
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Role of Subtype Classification in Small-Sized Pathologic N0 Invasive Lung Adenocarcinoma.
Yoshiya T; Mimae T; Tsutani Y; Tsubokawa N; Sasada S; Miyata Y; Kushitani K; Takeshima Y; Murakami S; Ito H; Nakayama H; Okada M
Ann Thorac Surg; 2016 Nov; 102(5):1668-1673. PubMed ID: 27344277
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients.
Yamauchi Y; Safi S; Muley T; Warth A; Herth FJF; Dienemann H; Hoffmann H; Eichhorn ME
Lung Cancer; 2017 Dec; 114():62-67. PubMed ID: 29173768
[TBL] [Abstract][Full Text] [Related]
8. Elevated MACC1 expression predicts poor prognosis in small invasive lung adenocarcinoma.
Guo T; Zhao S; Li Z; Li F; Li J; Gu C
Cancer Biomark; 2018; 22(2):301-310. PubMed ID: 29630522
[TBL] [Abstract][Full Text] [Related]
9. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.
Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Yan W; Liang Z; Xiong H; Chen K
Tumour Biol; 2015 Sep; 36(10):8085-92. PubMed ID: 25982999
[TBL] [Abstract][Full Text] [Related]
10. Validation of a molecular and pathological model for five-year mortality risk in patients with early stage lung adenocarcinoma.
Bueno R; Hughes E; Wagner S; Gutin AS; Lanchbury JS; Zheng Y; Archer MA; Gustafson C; Jones JT; Rushton K; Saam J; Kim E; Barberis M; Wistuba I; Wenstrup RJ; Wallace WA; Hartman AR; Harrison DJ
J Thorac Oncol; 2015 Jan; 10(1):67-73. PubMed ID: 25396679
[TBL] [Abstract][Full Text] [Related]
11. Solid component and tumor size correlate with prognosis of stage IB lung adenocarcinoma.
Xu S; Xi J; Jiang W; Lu S; Wang Q
Ann Thorac Surg; 2015 Mar; 99(3):961-7. PubMed ID: 25633461
[TBL] [Abstract][Full Text] [Related]
12. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.
Zhang Y; Sun Y; Li Y; Fang Z; Wang R; Pan Y; Hu H; Luo X; Ye T; Li H; Wang L; Chen H; Ji H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S577-82. PubMed ID: 23775406
[TBL] [Abstract][Full Text] [Related]
13. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma.
Yeh YC; Kadota K; Nitadori J; Sima CS; Rizk NP; Jones DR; Travis WD; Adusumilli PS
Eur J Cardiothorac Surg; 2016 Jan; 49(1):e9-e15. PubMed ID: 26377636
[TBL] [Abstract][Full Text] [Related]
14. Serum miR-142-3p is associated with early relapse in operable lung adenocarcinoma patients.
Kaduthanam S; Gade S; Meister M; Brase JC; Johannes M; Dienemann H; Warth A; Schnabel PA; Herth FJ; Sültmann H; Muley T; Kuner R
Lung Cancer; 2013 May; 80(2):223-7. PubMed ID: 23410826
[TBL] [Abstract][Full Text] [Related]
15. IL-11 and CCL-1: Novel Protein Diagnostic Biomarkers of Lung Adenocarcinoma in Bronchoalveolar Lavage Fluid (BALF).
Pastor MD; Nogal A; Molina-Pinelo S; Quintanal-Villalonga Á; Meléndez R; Ferrer I; Romero-Romero B; De Miguel MJ; López-Campos JL; Corral J; García-Carboner R; Carnero A; Paz-Ares L
J Thorac Oncol; 2016 Dec; 11(12):2183-2192. PubMed ID: 27524264
[TBL] [Abstract][Full Text] [Related]
16. Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease.
Weiss G; Schlegel A; Kottwitz D; König T; Tetzner R
J Thorac Oncol; 2017 Jan; 12(1):77-84. PubMed ID: 27544059
[TBL] [Abstract][Full Text] [Related]
17. Mitosis trumps T stage and proposed international association for the study of lung cancer/american thoracic society/european respiratory society classification for prognostic value in resected stage 1 lung adenocarcinoma.
Duhig EE; Dettrick A; Godbolt DB; Pauli J; van Zwieten A; Hansen AR; Yang IA; Fong KM; Clarke BE; Bowman RV
J Thorac Oncol; 2015 Apr; 10(4):673-81. PubMed ID: 25514800
[TBL] [Abstract][Full Text] [Related]
18. Combination of protein coding and noncoding gene expression as a robust prognostic classifier in stage I lung adenocarcinoma.
Akagi I; Okayama H; Schetter AJ; Robles AI; Kohno T; Bowman ED; Kazandjian D; Welsh JA; Oue N; Saito M; Miyashita M; Uchida E; Takizawa T; Takenoshita S; Skaug V; Mollerup S; Haugen A; Yokota J; Harris CC
Cancer Res; 2013 Jul; 73(13):3821-32. PubMed ID: 23639940
[TBL] [Abstract][Full Text] [Related]
19. Serum proteomic profiling of lung cancer in high-risk groups and determination of clinical outcomes.
Jacot W; Lhermitte L; Dossat N; Pujol JL; Molinari N; Daurès JP; Maudelonde T; Mangé A; Solassol J
J Thorac Oncol; 2008 Aug; 3(8):840-50. PubMed ID: 18670301
[TBL] [Abstract][Full Text] [Related]
20. CD24, a novel cancer biomarker, predicting disease-free survival of non-small cell lung carcinomas: a retrospective study of prognostic factor analysis from the viewpoint of forthcoming (seventh) new TNM classification.
Lee HJ; Choe G; Jheon S; Sung SW; Lee CT; Chung JH
J Thorac Oncol; 2010 May; 5(5):649-57. PubMed ID: 20354454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
